NCT07123090 2026-02-27
SPARCC
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
Clinical Trials
14 trialsNCT06962787 2025-11-17
A Study of BL-B01D1+TKIĀ±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04337970 2025-05-28
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02535533 2025-05-20
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1 Completed
NCT05969496 2025-04-04
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05941637 2024-12-31
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
Lynkcell Europe
No longer available
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT04385654 2020-05-13
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
West China Hospital
Phase 2 Unknown
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT00282048 2012-07-31
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Pfizer
Phase 2 Completed